Asian Fund for Cancer Research (AFCR) shared a post on LinkedIn:
“Pioneer Oncology – a disruptive ‘first-in-human clinical trial’ platform led by AFCR that brings a multi-drug parallel testing strategy to the early clinical stage (Phase 0 and Phase 1) to accelerate the discovery of new therapies and avoid patient exposure to ineffective treatments.
Pioneering in Hong Kong and expanding to Asia, Pioneer Oncology combines world-class clinical infrastructure, AI-driven analytics, and biomarker-guided precision medicine to bring breakthrough therapies to patients faster.
Supporting cancer research and bringing hope to patients.”
More posts featuring AFCR.